ESTRO meets Asia 2024 - Abstract Book

S175

Interdisciplinary – Head & neck

ESTRO meets Asia 2024

Hydrogen (H 2 ) gas inhalation might have alleviated the acute radiotherapy toxicities by scavenging the free radicals produced by ionizing radiation and anti-inflammatory properties. This study aimed to investigate the feasibility and safety of H 2 gas inhalation during concurrent chemoradiotherapy (CCRT) in locally advanced head and neck cancer (LAHNC) patients.

Material/Methods:

We designed the prospective quasi-experimental study of combining CCRT with aerosol inhalation of H 2 gas . Each patient was planned to receive daily radiation therapy (RT) in a total of 33 fractions on a weekday and 6 cycles of weekly chemotherapy. All patients inhaled H 2 gas through a canula or mask 1 hour per day, 1-2 hours before RT. The primary endpoint was the feasibility of H 2 gas inhalation. Eighty percent of patients completing at least 20 applications of H 2 gas inhalation were considered feasible. The secondary endpoints were safety profiles during H 2 gas inhalation (vital signs and any symptoms related to H 2 gas inhalation) and acute toxicities during CCRT.

Results:

We enrolled 10 LAHNC patients from July 2023 to December 2023. All patients could receive 33 fractions of H 2 gas inhalation on the same day of RT. The vital signs during and at the end of H 2 gas inhalation were stable in all patients. All 10 patients did not have hypertension nor hypotension in all 33 inhalations. No any adverse events related to H 2 gas inhalation, i.e., cough, nasal bleeding, dizziness, headache, nausea and vomiting were reported. Grade 3 leucopenia was found in 2 patients (20%) during the 5 th week of CCRT. Grade 2 radiation dermatitis and pharyngitis were found in 3 patients (30%).

Conclusion:

H 2 gas inhalation is feasible and safe for LAHNC patients who treated with CCRT.

Keywords: Hydrogen gas, feasibility, head and neck cancer

253

Digital Poster

Pembrolizumab with chemoradiation in locally advanced head and neck cancer: HNIT-01 interim analysis

Mustafa Elsherify 1 , Hamdy Sakr 1 , Amany Hussein 1 , Ahmad Bushehri 1 , Jitendra Shete 1 , Sheeba Gilbert 2 , Chacko Varghese 3 , Quratulain Faisal 1 , Mohammed Irfanullah 1 , Amr Shaaban 1 , Diyviasheree Narayan 1 , Fatima Batool 1 , Khaled Alsaleh 1 1 Radiation Oncology, Kuwait Cancer Control Center, Kuwait, Kuwait. 2 Specialized Nurse, Kuwait Cancer Control Center, Kuwait, Kuwait. 3 Radiation Technology, Kuwait Cancer Control Center, Kuwait, Kuwait

Purpose/Objective:

Head and neck cancers (HNC) shows very distinguishable geographic variation between East and West, in both etiological and risk factors and sub-site dominance. West Asia and Middle East countries are bridging between the East and West with mixed population of Caucasian and Asian ethnicity. Our phase II trial was designed to test the safety and efficacy of PD-1 inhibitor pembrolizumab add to the standard radical chemoradiation (CRT) in locally